In our study, we found that teniposide has a potential therapeutic effect on A-HCC by down-regulating the expression of A-HCC core genes (DNMT1 and EZH2), thereby reversing the malignant degree of A-HCC and improving the prognosis. This evidence concerns the gene DNMT1 and hepatocellular carcinoma.